Cite
HARVARD Citation
Kaseb, A. et al. (2013). Modified cisplatin/interferon α‐2b/doxorubicin/5‐fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer. 119 (18), pp. 3334-3342. [Online].